Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice.

Slides:



Advertisements
Similar presentations
DC Responses Received WA OR ID MT WY CA NV UT CO AZ NM AK HI TX ND SD NE KS OK MN IA MO AR LA WI IL MI IN OH KY TN MS AL GA FL SC NC VA WV PA NY VT NH.
Advertisements

Clinical and Translational Science Awards (CTSA) Anthony Hayward October 30, 2007.
CLINICAL & TRANSLATIONAL SCIENCE AWARDS CLINICAL & TRANSLATIONAL SCIENCE AWARDS Transforming Biomedical Research To Improve the Health of Our Nation’s.
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
Conducting a Study Safely and Efficiently at Johns Hopkins Daniel E Ford, MD, MPH Vice Dean for Clinical Investigation July 20, 2010.
National TIM Responder Training Program Implementation Progress - As of November 2, 2015 Train-the-Trainer Sessions 193 sessions with 7,115 participants.
National TIM Responder Training Program Implementation Progress - As of February 8, 2016 Train-the-Trainer Sessions 203 sessions with 7,306 participants.
National Journal Presentation Credits Producers: Katharine Conlon Director: Afzal Bari House Committee Maps Updated: March 19, 2015.
Uninsured Non-Elderly Adult Rate Increased from 17. 8% to 20
Medicaid Eligibility for Working Parents by Income, January 2013
Train-the-Trainer Sessions 240 sessions with 8,187 participants
WY WI WV WA VA VT UT TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
WY WI WV WA VA VT UT TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
Children's Eligibility for Medicaid/CHIP by Income, January 2013
The State of the States Cindy Mann Center for Children and Families
Train-the-Trainer Sessions 384 sessions with 11,279 participants
Train-the-Trainer Sessions 379 sessions with 11,183 participants
Train-the-Trainer Sessions 386 sessions with 11,336 participants
Non-Citizen Population, by State, 2011
Status of State Medicaid Expansion Decisions
Share of Women Ages 18 – 64 Who Are Uninsured, by State,
Coverage of Low-Income Adults by Scope of Coverage, January 2013
WY WI WV WA VA* VT UT TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
WY WI WV WA VA VT UT TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
Mobility Update and Discussion as of March 25, 2008
IAH CONVERSION: ELIGIBLE BENEFICIARIES BY STATE
Train-the-Trainer Sessions 362 sessions with 10,873 participants
State Health Insurance Marketplace Types, 2015
State Health Insurance Marketplace Types, 2018
HHGM CASE WEIGHTS Early/Late Mix (Weighted Average)
Status of State Medicaid Expansion Decisions
Train-the-Trainer Sessions 386 sessions with 11,336 participants
Train-the-Trainer Sessions 394 sessions with 11,460 participants
Train-the-Trainer Sessions 392 sessions with 11,432 participants
Status of State Medicaid Expansion Decisions
Medicaid Income Eligibility Levels for Parents, January 2017
Current Status of State Medicaid Expansion Decisions
State Health Insurance Marketplace Types, 2017
(map is coded by CAE-CD region)
S Co-Sponsors by State – May 23, 2014
WY WI WV WA VA VT UT* TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
Seventeen States Had Higher Uninsured Rates Than the National Average in 2013; Of Those, 11 Have Yet to Expand Eligibility for Medicaid AK NH WA VT ME.
Employer Premiums as Percentage of Median Household Income for Under-65 Population, 2003 and percent of under-65 population live where premiums.
Train-the-Trainer Sessions 396 sessions with 11,504 participants
Employer Premiums as Percentage of Median Household Income for Under-65 Population, 2003 and percent of under-65 population live where premiums.
Average annual growth rate
Train-the-Trainer Sessions 250 sessions with 8,352 participants
Market Share of Two Largest Health Plans, by State, 2006
Percent of Children Ages 0–17 Uninsured by State
Train-the-Trainer Sessions 402 sessions with 11,649 participants
Current Status of State Medicaid Expansion Decisions
Current Status of State Medicaid Expansion Decisions
How State Policies Limiting Abortion Coverage Changed Over Time
Status of State Medicaid Expansion Decisions
Train-the-Trainer Sessions 402 sessions with 11,649 participants
Employer Premiums as Percentage of Median Household Income for Under-65 Population, 2003 and percent of under-65 population live where premiums.
Percent of Adults Ages 18–64 Uninsured by State
Uninsured Nonelderly Adult Rate Has Increased from Percent to 20
Train-the-Trainer Sessions 401 sessions with 11,639 participants
Status of State Medicaid Expansion Decisions
WY WI WV WA VA VT UT* TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
WY WI WV WA VA VT UT* TX TN SD SC RI PA OR* OK OH ND NC NY NM* NJ NH
Train-the-Trainer Sessions 416 sessions with 11,878 participants
Current Status of State Individual Marketplace and Medicaid Expansion Decisions, as of September 30, 2013 WY WI WV WA VA VT UT TX TN SD SC RI PA OR OK.
Status of State Medicaid Expansion Decisions
Income Eligibility Levels for Children in Medicaid/CHIP, January 2017
WY WI WV WA VA VT UT TX TN SD SC RI PA OR OK OH ND NC NY NM NJ NH NV
Train-the-Trainer Sessions 429 sessions with 12,141 participants
Train-the-Trainer Sessions 436 sessions with 12,254 participants
Train-the-Trainer Sessions 386 sessions with 11,336 participants
Presentation transcript:

Clinical and Translational Research: Expectations and Goals Daniel E. Ford, M.D., M.P.H. Director, Institute for Clinical and Translational Research Vice Dean for Clinical Investigation

Clinical Research at Johns Hopkins Comprehensive in Scope Cancer Center Research in children Neurosciences Drug abuse Investigator Initiated Large Discovery Pipeline Expertise in Moving Discoveries to Population Fortunate to Have Large Number of Trainees Interested in Research

Research at ClOffJohns Hopkins Medicine By Calendar Year Last updated 4/5/2010 New Applications NHSR New Exempt New Expedited New Convened Total New Applications Active eIRB Applications Active Paper Applications Active SOM IRB WIRB Active Applications CIRB Active Applications Total Active Randomized Clinical Trials Active Randomized Clinical Trials New Randomized Clinical Trials

Commercial Applications Active Commercial New Commercial Commercial Clinical Trials Active Commercial Clinical Trials New Commercial Clinical Trials Using Drugs/Devices Active Applications Using Drugs New Applications Using Drugs Active Applications using Devices New Applications using Devices IDE/INDs Applications Investigator/Sponsor HeldActive Applications using INDs New Applications using INDs Active INV Held INDs New INV Held INDs Active Applications using IDEs New Applications using IDEs Active INV Held IDEs New INV Held IDEs 332

Sponsored Project Sources Johns Hopkins SOM – Prorated Awards

Translational Medicine T1 – “the transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention and their first testing in humans.” T2 – “the translation of results from clinical studies into everyday clinical practice and health decision making.” IOM Clinical Research Roundtable

Translational Research Activities T1 activities included: 1) the translation of basic discovery into mechanistic studies in cell lines or animals, 2) the translation of mechanistic studies into initial human testing, and 3) the translation of initial human testing into proof of efficacy. The T2 activities included 1) the translation of proof of efficacy into proof of effectiveness in a usual care setting, and 2) research aimed at enhancing the adoption of best practices in the community

Conclusions 69% responded they are translational researchers (9% other survey but different definition) PhD and fellows report less translational activity Barriers to translational research are as expected but substantial

Translational research is not part of my research agenda or is not central to the goals of my research program. I don’t have the resources (funding, space, equipment, technology) for making my research more translational. I have not yet identified an appropriate translational research question to pursue. I am not sure what the next translational step would be for my research. I haven’t identified or secured the colleagues or collaborators I need to make my work more translational. I don’t have the guidance or mentorship I need to make my research more translational. I don’t have the training or expertise I need to make my work more translational. I have methodological obstacles to making my research more translational. It is premature for me to consider translational research. Number of Respondents (n=205) It is premature for me to consider translational research. I have methodological obstacles to making my research more translational. I don’t have the training or expertise I need to make my research more translational. I don’t have the guidance or mentorship I need to make my research more translational. I haven’t identified or secured the colleagues or collaborators I need to make my work more translational. I am not sure what the next translational step is I have not yet identified an appropriate translational research question to pursue. I don’t have the resources (funding, space, equipment, technology) for making my research more translational. Translational research is not part of my research agenda or is not central to the goals of my research program. Barriers to Translational Research (n=205)

Translational Pathway Basic Discovery Mechanistic Studies Initial Human Testing Proof of Efficacy Proof of Effectiveness Diffusion to All Health Care Settings 2 1

Institute for Clinical and Translational Research Influence on Scientific Discovery Institute Programs Enhancing Formulation ofCreation of Development Conduct Analysis of Publication Observation Scientific Question Research Team Study Protocol of Study Study Data Impact Study Advisory Boards Protocol Review Translational Science Forums Science Cores Innovation Groups Biostatistical Support Regulatory Support ATIP Research Ethics Clinical Research Units Clinical Research Participant Core Data/Safety Monitoring Community Engagement Program Biomedical Informatics Navigator Program Research Education and Training

Impetus for the CTSA Program  Implementing biomedical discoveries made in the last 10 years demands an evolution of clinical science.  New prevention strategies and treatments must be developed, tested, and brought into medical practice more rapidly.  CTSA awards will lower barriers between disciplines, and encourage creative, innovative approaches to solve complex medical problems.  These clinical and translational science awards will catalyze change -- breaking silos, breaking barriers, and breaking conventions.

Johns Hopkins and Translational Medicine Need to support researchers at all career levels Progress in translational medicine requires development of teams of researchers that appreciate all phases Clinical and translational researchers will continue to develop more technical and specialized approaches. Handoffs require active coordination (project coordinators). Do to increasing regulations, researchers will need to rely more on systematized solutions at institutional or national level Academic organizations need to partner better with other organizations to increase efficiency (industry, payers, patient groups) Need to balance resources/support for early and late translation Academic centers need better management structure to systematically monitor research process and barriers

MT WY ID WA OR NV UT CA AZ ND SD NE CO NM TX OK KS AR LA MO IA MN WI IL IN KY TN MS AL GA FL SC VA WV OH MI NY PA MD DE NJ CT RI MA ME VT NH AK HI Building a National CTSA Consortium Since 2006 Since 2007 Participating Institutions

CTSAWeb.org

Consortium Governance & Organization Governance Manual available at

Institute for Clinical and Translational Research Goals –Academic Home for Clinical and Translational Researchers –Expand the Working Relationships of Clinical Investigators with Basic Scientists and Population-oriented Scientists –Coordinate Translational Research Activities to Increase Innovation and Speed of Translation

Institute for Clinical and Translational Research Goals –Support Training of Clinical and Translational Research Faculty and Staff –Provide Centralized Support for Research Where Efficient –Measure and Track Efficiency of Human Subjects Research to Address Barriers Director – Daniel Ford, MD, MPH Vice Dean for Clinical Investigation

Deputy Directors of the Institute for Clinical and Translational Research Dr. Charles Balch Dr. Stephen Desiderio Dr. Charles Flexner Dr. Elizabeth Jaffee Dr. Pete Miller Dr. Pamela Ouyang Dr. Jeff Rothstein Dr. Pamela Zeitlin

Trial Design Advanced Degree-Granting Programs Participant & Community Involvement Regulatory Support Biostatistics Clinical Resources Biomedical Informatics Research participant Recruitment office Johns Hopkins ICTR ICTR NIH & other government agencies Healthcare organizations Industry Johns Hopkins Institute for Clinical and Translational Research

Johns Hopkins ICTR Progams Translational research training –K junior faculty/fellows –Medical students –Research staff and community physicians Clinical Research Units –1200 inpatient research bed days –Over 10,000 outpatient research visits –Pediatric and adult beds including Bayview

Johns Hopkins ICTR Progams Biostatistical Consultation Innovative Methodology Workgroups Clinical Research Ethics Consultations Data and Safety Monitoring Services Translational Research Navigators (project managers) Clinical Research Management Database

Johns Hopkins ICTR Progams Basic Discovery Translational Forum Clinical Sciences Translational Forum Accelerated Translational Incubator Program (ATIP) support pilots Research Participant Recruitment and Retention Program Community Research Networks Office Secondary Translation or Knowledge Transfer Office

Clinical Research Management System Budgeting Sponsor Billing InvestigatorsResearch Nurse Data Manager Insurance Clearance Budgeting by Dept. Admin. Program Manager Patient/ Protocol Registry PharmacyCore Facilities Labs SoM Leadership Billing Compliance IRB Eligibility Screening EPR/Labs Integration IRB Integration Protocol Schema / Patient Calendar Billing Compliance External Recruiting Website JHED/Site Minder Integration Data Warehouse Library Research Forms Work In Progress Currently In Use Possible Future Functionality Key:

Translational Cores Genetics Core Proteomics/Biomarker Core Drug and Vaccine Development Core